Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Medication


FORXIGA™ approved in EU for treatment of T2D

November 15th 2012

FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes (AstraZeneca and Bristol-Myers Squibb)

Categories: Medication, News

Categories: Medication

Long-Acting Insulins Win FDA Panel Support

November 10th 2012

An FDA advisory committee voted 8-4 Thursday in favor of approval of a new ultra-long-acting insulin for type 1 and type 2 diabetes. (medpage TODAY)

Categories: Medication, News

Categories: Medication

Type 2 diabetes: insulin degludec

November 9th 2012

This evidence summary considers the use of insulin degludec in adults with type 2 diabetes (NICE)

Categories: Medication, News

Categories: Medication

Type 1 diabetes: insulin degludec

November 9th 2012

This evidence summary considers the use of insulin degludec in adults with type 1 diabetes (NICE)

Categories: Medication, News

Categories: Medication

Drug offers new pain management therapy for diabetics

November 1st 2012

The medication used in the study has the generic name nabilone, and is currently used in Canada to treat nausea in chemotherapy patients. This study gives doctors more evidence to support its prescription for treating neuropathy pain in diabetics (University of Calgary, Hotchkiss Brain Institute)

Categories: Medication, News

Categories: Medication

Metformin Compared with Insulin Treatment of Pregnant Women with Diabetes

October 25th 2012

A randomized controlled trial suggests that metformin should be considered for treatment of overt diabetes and early a2 gestational diabetes in pregnancy (American Journal of Perinatology)

Categories: Medication, News

Categories: Medication

Metformin Stimulates FGF21 Expression in Primary Hepatocytes

October 15th 2012

Metformin is a potent inducer of hepatic FGF21 expression and that the effect of metformin seems to be mediated through AMPK activation (Experimental Diabetes Research)

Categories: Medication, News

Categories: Medication

Sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

October 15th 2012

This study is the first to show that a DPP-4 inhibitor, sitagliptin, reduces inflammatory cytokines and improves the unfavorable M1/M2-like phenotypes of peripheral blood monocytes in Japanese type 2 diabetic patients (Metabolism – Clinical and Experimental)

Categories: Medication, News

Categories: Medication

Boston Therapeutics Wins FDA Approval for PAZAMET

October 8th 2012

In addition, the FDA has ruled that no further clinical investigation is necessary to demonstrate the safety and effectiveness of this proposed product (Boston Therapeutics)

Categories: Medication, News

Categories: Medication

Outcomes Data for Investigational Novel Basal Insulin Analogue

October 2nd 2012

The study results showed that in addition to clinical results showing a statistically significant 48 percent baseline adjusted reduction in nocturnal hypoglycaemia compared with insulin glargine patients treated with LY2605541* reported a statistically significant reduction in the anxiety and fear associated with experiencing a hypoglycaemic event based upon the Adult Low Blood Sugar Survey (Lilly)

Categories: Medication, News

Categories: Medication

Studies assess linagliptin treatment in adults with T2D

October 2nd 2012

The new analyses show linagliptin, alone or in combination with other diabetes therapies, lowered hemoglobin A1c (HbA1c or A1C) in elderly patients with type 2 diabetes, as well as in adults with type 2 diabetes with diabetic nephropathy (renal disease).Data from a fourth study found adding linagliptin to a stable dose of basal insulin improved blood glucose control over 52 weeks without an additional risk of hypoglycemia or weight gain compared to placebo (Lilly)

Categories: Medication, News

Categories: Medication

Recent advances in incretin-based therapies

September 27th 2012

This review provides an overview of the development of incretin-based therapies and explains their differing modes of action compared with traditional interventions (Clinical Endocrinology)

Categories: Medication, News

Categories: Medication

Novartis – 2 CHMP positive opinions for new indications of Galvus® and Eucreas®

September 21st 2012

Novartis announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions for new indications for the use of Galvus® (vildagliptin) and Eucreas® (vildagliptin and metformin) in combination with other treatments for type 2 diabetes patients (Novartis)

Categories: Medication, News

Categories: Medication

Effectiveness & safety of metformin in T2D & different levels of renal function

September 18th 2012

A cohort study from the Swedish National Diabetes Register (BMJ)

Categories: Medication, News

Categories: Medication

Liraglutide in T2D controlled on metformin improves vascular function markers

September 6th 2012

In patients with Type 2 diabetes, well controlled with metformin monotherapy, addition of liraglutide improves several cardiovascular risk markers beyond glycaemic control (Diabetic Medicine)

Categories: Medication, News

Categories: Medication

New data for Novartis drug Lucentis® confirms long-term efficacy and safety

September 5th 2012

New data for Lucentis® (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections. It is estimated that over 80% of visual impairment is preventable when due to conditions such as … diabetic macular edema (DME)

Categories: Medication, News

Categories: Medication

Diabetes Drugs Prescribed to Millions of Americans Raises Bladder Cancer Risks

August 17th 2012

Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs – which account for up to 20 percent of the drugs prescribed to diabetics in the United States — are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes (University of Pennsylvania)

Categories: Medication, News

Categories: Medication

FDA approves Lucentis to treat diabetic macular edema

August 13th 2012

An injection administered once a month by a health care professional, Lucentis is intended to be used along with good diabetic blood sugar control (FDA)

Categories: Medication, News

Categories: Medication

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes

August 8th 2012

Glycemic control, weight, and treatment satisfaction improved after switching from sitagliptin to liraglutide, albeit with a transient increase in gastrointestinal reactions (Diabetes Care)

Categories: Medication, News

Categories: Medication

Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients

August 7th 2012

The results from both studies confirm that imeglimin displays a superior benefit : risk profile compared with metformin in type 2 diabetes patients. The encouraging tolerability profile of imeglimin could make it suitable for combination with other classes of antidiabetic agents and may increase availability to a wider patient population (Diabetes, Obesity and Metabolism)

Categories: Medication, News

Categories: Medication
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskMSDAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Sanofi DiabetesAmgenAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI cancer carbohydrate CGM closed-loop dapagliflozin DPP4 Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy RYGB semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 Glycosmedia Partnership